Clinical trial
Vaccine Therapy in Treating Patients With Malignant Melanoma
NCT00128583 · CancerVax Corporation, Industry · Unknown status
Key facts
| NCT number | NCT00128583 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Malignant Melanoma |
| Official title | Response of In-Transit Melanoma to Systemic Treatment With the Specific Active Immunotherapeutic Agent, Canvaxin™ |
| Lead sponsor | CancerVax Corporation, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | polyvalent melanoma vaccine |
| Start date | Jul 1, 2005 |
| First posted | Aug 10, 2005 |
| Last update posted | Dec 19, 2013 |
| Countries | Australia, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: